Leadership with experience across antibody discovery, antiviral development, and commercialization

Ronald Moss, M.D.

Chief Executive Officer and President

• Physician-scientist who has led antiviral and vaccine programs from early-stage research through late-stage clinical trials and NDA/BLA submission.
• Has held executive positions at Merck and chief executive positions at Red Queen Therapeutics, Diosynvax, and Ansun Biopharma.
• Experience obtaining BARDA and NIH funding and raising capital in both public and private biotechnology companies.

Andrew de Guttadauro

Chief Business Officer

• Biopharmaceutical executive with more than 30 years of commercialization and business development experience.
• Led the marketing team that took Enbrel past the billion-dollar revenue threshold.
• Negotiated licensing agreements with major biopharmaceutical companies while at Vical and Oncolytics.

Klaus Frueh, Ph.D.

Chief Scientific Officer

Professor, Oregon Health and Science University

• Immunologist and virologist conducting research in infectious disease and cancer immunotherapy.
• Co-founder of Vir Biotechnology.

James Crowe, M.D.

Inventor

Ann Scott Carell Professor; Professor of Pediatrics and of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center

• Leads a human monoclonal antibody discovery program from which Saravir's measles antibodies originated.
• Elected to the National Academy of Medicine in 2014 and the National Academy of Inventors in 2017; elected fellow of AAM, AAAS, ASCI, AAP, IDSA, APS.
• Awarded the 2019 Merck Future Insight Prize for Pandemic Preparedness, shared with Pardis Sabeti of the Broad Institute.

Anne Moscona, M.D.

Scientific adviser

Sherie L. Morrison Professor of Microbiology and Immunology, Professor of Pediatrics, and Professor of Physiology and Biophysics, Columbia University

• Virologist whose studies of paramyxovirus entry informed the design of entry-blocking strategies.
• Past President, American Society of Virology.